八宝五胆药墨联合依匹斯汀治疗寻常型银屑病的临床研究
|
摘要
目的探讨八宝五胆药墨联合依匹斯汀治疗寻常型银屑病的临床疗效。方法将2016年1月—2018年1月我院收治的206例寻常型银屑病患者随机分为治疗组和对照组。对照组给予依匹斯汀治疗,观察组则另给予八宝五胆药墨治疗,2组均治疗8周。治疗后,评价2组临床疗效。治疗期间,对2组患者的症状缓解时间进行观察,主要观察项目为瘙痒、红斑、脱屑、渗出及干燥。治疗前后,分别检测2组炎症指标含量,主要检测指标为肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6、IL-17及干扰素(IFN)-γ;检测2组患者银屑病相关指标,主要检测指标为血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)、脂质过氧化产物(LPO)及载脂蛋白A1(ApoA1)。治疗期间,密切观察2组患者不良反应。结果治疗后,治疗组总有效率明显高于对照组(P<0.05)。治疗期间,治疗组瘙痒、红斑、脱屑及干燥等症状缓解时间均明显短于对照组(P<0.05)。治疗后,治疗组TNF-α、IL-6、IL-17及IFN-γ均明显低于对照组(P<0.05),而VEGF、bFGF、LPO及ApoA1含量亦均明显低于对照组(P<0.05)。治疗期间,所有患者均未出现明显药物不良反应。结论八宝五胆药墨联合依匹斯汀治疗寻常型银屑病的疗效较好,值得开展深入研究。
Objective In order to observe the effects of Babao Wudan Yaomo combined with epistine in the treatment of psoriasis vulgaris. Methods A total of 206 patients with psoriasis vulgaris from Jan. 2016 to Jan. 2018 in our hospital were randomly divided into treatment group and control group. The control group was treated by epistine,and treatment group was treated by Babao Wudan Yaomo on the basis of control group,the treatment course was eight weeks. After treatment,the effects of patients were observed. During the treatment,the symptom remission time of the two groups were observed,including pruritus,erythema,dandruff and dryness. Before and after treatment,the levels of inflammation markers were detected,including tumor necrosis factor-alpha(TNF-α),interleukin-6(IL-6),interleukin-17(IL-17) and interferon alpha(IFN-γ),while the levels of psoriasis vulgaris makers,including vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF),lipid peroxidation product(LPO) and apolipoprotein A1(ApoA1) were also detected. The adverse reactions of the two groups were closely observed during the treatment. Results After the treatment,the effective rate was significantly higher in treatment group than control group(P<0.05). After the treatment,the TNF-α,IL-6,IL-17 and IFN-γ levels were significantly lower in treatment group than control group(P<0.05),while the levels of VEGF,bFGF,LPO and ApoA1 were also significantly lower in treatment group than control group(P<0.05). During the treatment,the rates of adverse actions were similar in the two groups. Conclusion Babao Wudan Yaomo combined with epistine in the treatment of psoriasis vulgaris is affirmative,worth to the further research.
Objective In order to observe the effects of Babao Wudan Yaomo combined with epistine in the treatment of psoriasis vulgaris. Methods A total of 206 patients with psoriasis vulgaris from Jan. 2016 to Jan. 2018 in our hospital were randomly divided into treatment group and control group. The control group was treated by epistine,and treatment group was treated by Babao Wudan Yaomo on the basis of control group,the treatment course was eight weeks. After treatment,the effects of patients were observed. During the treatment,the symptom remission time of the two groups were observed,including pruritus,erythema,dandruff and dryness. Before and after treatment,the levels of inflammation markers were detected,including tumor necrosis factor-alpha(TNF-α),interleukin-6(IL-6),interleukin-17(IL-17) and interferon alpha(IFN-γ),while the levels of psoriasis vulgaris makers,including vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF),lipid peroxidation product(LPO) and apolipoprotein A1(ApoA1) were also detected. The adverse reactions of the two groups were closely observed during the treatment. Results After the treatment,the effective rate was significantly higher in treatment group than control group(P<0.05). After the treatment,the TNF-α,IL-6,IL-17 and IFN-γ levels were significantly lower in treatment group than control group(P<0.05),while the levels of VEGF,bFGF,LPO and ApoA1 were also significantly lower in treatment group than control group(P<0.05). During the treatment,the rates of adverse actions were similar in the two groups. Conclusion Babao Wudan Yaomo combined with epistine in the treatment of psoriasis vulgaris is affirmative,worth to the further research.
引文
[1]付玉娟,郑敏. 2016年银屑病临床研究进展回顾[J].皮肤病与性病,2017,39(1):12-14.
[2]鲁延富,伍斌,李林丽.银屑病中西医治疗研究进展[J].医学综述,2015,21(22):4 121-4 124.
[3]董祖木,赵月华.八宝五胆药墨外用治疗带状疱疹115例[J].中医药导报,2010,16(9):73.
[4]张辉,马小娜,刘波.脾氨肽口服液联合依匹斯汀治疗慢性荨麻疹的临床研究[J].现代药物与临床,2017,32(9):1 734-1 737.
[5]赵辨.中国临床皮肤病学[M].南京:江苏科学技术出版社,2009:1 008-1 009.
[6]吴少祯.常见疾病的诊断与疗效判定(标准)[M].北京:中国中医药出版社:1999:650-651.
[7]蔡莎莉.银屑病PASI评分观察表的设计与应用[J].护理学杂志,2013,28(1):78.
[8]中国医师协会皮肤科医师分会中西医皮肤科亚专业委员会.中成药治疗寻常性银屑病专家共识(2014)[J].中华皮肤科杂志,2014,47(3):215-216.
[9]王晓宁,郑伟娟,周映,等.银屑病发病机制和治疗方法的研究进展[J].药物生物技术,2015,22(3):259-263.
[10]黄桂新.银屑病病因与发病机制的研究进展[J].中国医药指南,2012,10(13):73-74.
[11]曹萍.银屑病治疗的策略[J].皮肤病与性病,2013,35(5):263-263.
[12]王卫亮,谢汝汉,刘奉彬,等.依匹斯汀联合复方氟米松软膏治疗寻常型银屑病的疗效及安全性[J].辽宁医学杂志,2017,3(2):7-8.
[13]时国朝,邓伟吾.第二代抗组胺药的最新研究概述[J].世界临床药物,2002,23(3):139-141.
[14]龙子江,张礼春,丁伯春,等.八宝五胆药墨抗肿瘤作用及对炎症因子的影响[J].中药与临床,2013,4(3):30-32.
[15]胡祥宇,杨文信.血清中肿瘤坏死因子α、干扰素γ及白介素4与寻常型银屑病中医辨证相关性研究[J].西南军医,2015,17(2):156-158.
[16]范团起,李卫红. IL-6及TNF-α与寻常性银屑病的关系[J].医药论坛杂志,2006,27(12):34-37.
[17]叶柱均,叶淑霞,陈丽仙,等. IL-17、IL-22和CRP在银屑病患者血清中的表达[J].国际检验医学杂志,2016,37(2):254-255.
[18]朱凡,郑敏,鲍彰.银屑病患者皮损中血管内皮生长因子受体的表达与血管增生的关系[J].中华皮肤科杂志,2003,36(7):365-367.
[19]彭立义,张道杰,叶明亮,等.银屑病患者LPO,MDA,SOD,GSH-Px及TNF水平测定[J].中国皮肤性病学杂志,1998,4(6):21-22.
[20]郭玮,周诣翔.银屑病患者血清及皮屑氧化应激指标、血流变指标的变化研究[J].实用临床医药杂志,2017,21(3):112-114.
[2]鲁延富,伍斌,李林丽.银屑病中西医治疗研究进展[J].医学综述,2015,21(22):4 121-4 124.
[3]董祖木,赵月华.八宝五胆药墨外用治疗带状疱疹115例[J].中医药导报,2010,16(9):73.
[4]张辉,马小娜,刘波.脾氨肽口服液联合依匹斯汀治疗慢性荨麻疹的临床研究[J].现代药物与临床,2017,32(9):1 734-1 737.
[5]赵辨.中国临床皮肤病学[M].南京:江苏科学技术出版社,2009:1 008-1 009.
[6]吴少祯.常见疾病的诊断与疗效判定(标准)[M].北京:中国中医药出版社:1999:650-651.
[7]蔡莎莉.银屑病PASI评分观察表的设计与应用[J].护理学杂志,2013,28(1):78.
[8]中国医师协会皮肤科医师分会中西医皮肤科亚专业委员会.中成药治疗寻常性银屑病专家共识(2014)[J].中华皮肤科杂志,2014,47(3):215-216.
[9]王晓宁,郑伟娟,周映,等.银屑病发病机制和治疗方法的研究进展[J].药物生物技术,2015,22(3):259-263.
[10]黄桂新.银屑病病因与发病机制的研究进展[J].中国医药指南,2012,10(13):73-74.
[11]曹萍.银屑病治疗的策略[J].皮肤病与性病,2013,35(5):263-263.
[12]王卫亮,谢汝汉,刘奉彬,等.依匹斯汀联合复方氟米松软膏治疗寻常型银屑病的疗效及安全性[J].辽宁医学杂志,2017,3(2):7-8.
[13]时国朝,邓伟吾.第二代抗组胺药的最新研究概述[J].世界临床药物,2002,23(3):139-141.
[14]龙子江,张礼春,丁伯春,等.八宝五胆药墨抗肿瘤作用及对炎症因子的影响[J].中药与临床,2013,4(3):30-32.
[15]胡祥宇,杨文信.血清中肿瘤坏死因子α、干扰素γ及白介素4与寻常型银屑病中医辨证相关性研究[J].西南军医,2015,17(2):156-158.
[16]范团起,李卫红. IL-6及TNF-α与寻常性银屑病的关系[J].医药论坛杂志,2006,27(12):34-37.
[17]叶柱均,叶淑霞,陈丽仙,等. IL-17、IL-22和CRP在银屑病患者血清中的表达[J].国际检验医学杂志,2016,37(2):254-255.
[18]朱凡,郑敏,鲍彰.银屑病患者皮损中血管内皮生长因子受体的表达与血管增生的关系[J].中华皮肤科杂志,2003,36(7):365-367.
[19]彭立义,张道杰,叶明亮,等.银屑病患者LPO,MDA,SOD,GSH-Px及TNF水平测定[J].中国皮肤性病学杂志,1998,4(6):21-22.
[20]郭玮,周诣翔.银屑病患者血清及皮屑氧化应激指标、血流变指标的变化研究[J].实用临床医药杂志,2017,21(3):112-114.